Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13,912 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: sato y. Cardiovasc Diabetol. 2021 Jan 4;20(1):4. doi: 10.1186/s12933-020-01206-1. Cardiovasc Diabetol. 2021. PMID: 33397376 Free PMC article. Clinical Trial.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K; SUCCESS Study Group. Kobayashi K, et al. Among authors: sato y. Diabetes Obes Metab. 2014 Aug;16(8):761-5. doi: 10.1111/dom.12264. Epub 2014 Feb 18. Diabetes Obes Metab. 2014. PMID: 24447683 Clinical Trial.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.
Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. Yokoh H, et al. Among authors: sato y. J Diabetes Investig. 2015 Mar;6(2):182-91. doi: 10.1111/jdi.12282. Epub 2014 Sep 24. J Diabetes Investig. 2015. PMID: 25802726 Free PMC article.
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A, Inoue T, Kitakaze M, Oyama J, Sata M, Taguchi I, Shimizu W, Watada H, Tomiyama H, Ako J, Sakata Y, Anzai T, Uematsu M, Suzuki M, Eguchi K, Yamashina A, Saito Y, Sato Y, Ueda S, Murohara T, Node K. Tanaka A, et al. Among authors: sato y. Cardiovasc Diabetol. 2016 Apr 4;15:57. doi: 10.1186/s12933-016-0381-x. Cardiovasc Diabetol. 2016. PMID: 27044332 Free PMC article. Clinical Trial.
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J, Tanaka A, Sato Y, Tomiyama H, Sata M, Ishizu T, Taguchi I, Kuroyanagi T, Teragawa H, Ishizaka N, Kanzaki Y, Ohishi M, Eguchi K, Higashi Y, Yamada H, Maemura K, Ako J, Bando YK, Ueda S, Inoue T, Murohara T, Node K; PRIZE Study Investigators. Oyama J, et al. Among authors: sato y. Cardiovasc Diabetol. 2016 Jun 18;15:87. doi: 10.1186/s12933-016-0409-2. Cardiovasc Diabetol. 2016. PMID: 27317093 Free PMC article. Clinical Trial.
Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).
Kanatsuka A, Sato Y, Kawai K, Hirao K, Kobayashi M, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group (JDDM); Abe N, Arai K, Fujiya H, Fukumoto Y, Dake F, Iizumi T, Ito M, Iwasaki K, Kanamori A, Kato S, Kato M, Kawara A, Kimura K, Chikamori K, Iemitsu K, Kou S, Kudo M, Kurihara Y, Lee G, Tsuruoka A, Manda N, Matoba K, Hayashi H, Minami M, Kuribayashi N, Miyazawa K, Chiba Y, Osonoi T, Nakamura S, Sasaki H, Komori K, Oishi M, Okada A, Okuguchi F, Yanagisawa M, Sugimoto H, Sugiyama H, Takai M, Takaki M, Takamura H, Takeda H, Takeda H, Tanaka K, Miwa T, Tomonaga O, Taguchi M, Yamazaki K, Wada T, Yagi N, Yamaoka K, Yuhara A. Kanatsuka A, et al. Among authors: sato y. J Diabetes Investig. 2016 May;7(3):386-95. doi: 10.1111/jdi.12430. Epub 2015 Nov 12. J Diabetes Investig. 2016. PMID: 27330726 Free PMC article.
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K; PROTECT Study Investigators. Tanaka A, et al. Among authors: sato y. Cardiovasc Diabetol. 2016 Sep 13;15(1):133. doi: 10.1186/s12933-016-0449-7. Cardiovasc Diabetol. 2016. PMID: 27619983 Free PMC article. Clinical Trial.
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K; EMBLEM Trial Investigators. Tanaka A, et al. Among authors: sato y. Cardiovasc Diabetol. 2017 Apr 12;16(1):48. doi: 10.1186/s12933-017-0532-8. Cardiovasc Diabetol. 2017. PMID: 28403850 Free PMC article. Clinical Trial.
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K; PRIME-V Study Investigators. Koshizaka M, et al. Among authors: sato y. BMJ Open. 2017 May 9;7(5):e015766. doi: 10.1136/bmjopen-2016-015766. BMJ Open. 2017. PMID: 28490565 Free PMC article. Clinical Trial.
Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ohashi M, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: sato y. Diabetes Ther. 2017 Oct;8(5):999-1013. doi: 10.1007/s13300-017-0292-1. Epub 2017 Sep 1. Diabetes Ther. 2017. PMID: 28864997 Free PMC article.
13,912 results
You have reached the last available page of results. Please see the User Guide for more information.